Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

The Quick Take
SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
UPS chief US domestic officer sells $876,627 in stock
Business
Brinker International CEO Kevin Hochman sells $8.8M in stock
Business
GlobalFoundries CLO Samak Azar sells $15,198 in shares
Business
Flooding sends water into Arts District small business shops - FOX5 Vegas
Flooding sends water into Arts District small business shops FOX5 Vegas
